United Therapeutics Corp
Company Overview
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. Their primary focus is on pulmonary arterial hypertension (PAH) and other cardiovascular diseases. The company develops and markets several FDA-approved medicines for treating PAH and related conditions.
The company's main products include Remodulin, Tyvaso, Orenitram, and Adcirca, which are all treatments for PAH. They also have a robust pipeline of products in development, including organ manufacturing projects aimed at addressing the shortage of transplantable organs.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $748.9m | $415.9m | - | $10.1m | 0.00% | 2.43% |
| June 30, 2024 | $714.9m | $406.6m | - | $11.6m | 0.00% | 2.85% |
| March 31, 2024 | $677.7m | $334.7m | - | $13.3m | 0.00% | 3.97% |
Company Impact
Help us evaluate United Therapeutics Corp's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.